Limits...
Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.

Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière PO, Rudant J, Alla F, Zureik M - BMJ (2016)

Bottom Line: After adjustment for oestrogen dose and risk factors, desogestrel and gestodene were associated with statistically significantly higher relative risks for pulmonary embolism (2.16, 1.93 to 2.41 and 1.63, 1.34 to 1.97, respectively) compared with levonorgestrel.Levonorgestrel combined with 20 µg oestrogen was associated with a statistically significantly lower risk than levonorgestrel with 30-40 µg oestrogen for each of the three serious adverse events.  For the same dose of oestrogen, desogestrel and gestodene were associated with statistically significantly higher risks of pulmonary embolism but not arterial thromboembolism compared with levonorgestrel.For the same type of progestogen, an oestrogen dose of 20 µg versus 30-40 µg was associated with lower risks of pulmonary embolism, ischaemic stroke, and myocardial infarction.

View Article: PubMed Central - PubMed

Affiliation: Department of Studies in Public Health, French National Health Insurance, 75986 Paris Cedex 20, France alain.weill@cnamts.fr.

No MeSH data available.


Related in: MedlinePlus

Fig 1 Flow of participants through study
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4862376&req=5

f1: Fig 1 Flow of participants through study

Mentions: After exclusion and censoring of data (figure 1), the study cohort comprised 4 945 088 women with 5 443 916 women years of oral contraceptive use.


Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.

Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière PO, Rudant J, Alla F, Zureik M - BMJ (2016)

Fig 1 Flow of participants through study
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4862376&req=5

f1: Fig 1 Flow of participants through study
Mentions: After exclusion and censoring of data (figure 1), the study cohort comprised 4 945 088 women with 5 443 916 women years of oral contraceptive use.

Bottom Line: After adjustment for oestrogen dose and risk factors, desogestrel and gestodene were associated with statistically significantly higher relative risks for pulmonary embolism (2.16, 1.93 to 2.41 and 1.63, 1.34 to 1.97, respectively) compared with levonorgestrel.Levonorgestrel combined with 20 µg oestrogen was associated with a statistically significantly lower risk than levonorgestrel with 30-40 µg oestrogen for each of the three serious adverse events.  For the same dose of oestrogen, desogestrel and gestodene were associated with statistically significantly higher risks of pulmonary embolism but not arterial thromboembolism compared with levonorgestrel.For the same type of progestogen, an oestrogen dose of 20 µg versus 30-40 µg was associated with lower risks of pulmonary embolism, ischaemic stroke, and myocardial infarction.

View Article: PubMed Central - PubMed

Affiliation: Department of Studies in Public Health, French National Health Insurance, 75986 Paris Cedex 20, France alain.weill@cnamts.fr.

No MeSH data available.


Related in: MedlinePlus